Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2012-01557 | Registry Identifier | NCI CTRP |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Primary Objective:
To determine whether the use of a paravertebral block in patients undergoing reconstructive surgery for breast cancer results in decreased immediate post-operative pain compared with patients having only general anesthesia.
Secondary Objectives:
Paravertebral Blocks and General Anesthesia The use of a paravertebral block involves injecting local anesthesia (a numbing medicine) into the patient's back to numb specific areas (the breast[s] for this study) for surgery.
General anesthesia is medicine that is used to put patients to sleep so that there is no feeling of pain.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned (as in the toss of a coin) to 1 of 2 groups. You will have an equal (50/50) chance of being assigned to either group.
Participants in one group will receive a paravertebral block (the local anesthetic ropivacaine) plus general anesthesia.
Participants in the other group will receive general anesthesia (propofol, desflurane, and fentanyl) without a paravertebral block.
Drug Administration:
If you are assigned to receive the paravertebral block plus general anesthesia, you will have a paravertebral block placed just before surgery begins. Ropivacaine will be given by injection into the paravertebral space along the spinal canal.
If you are assigned to receive general anesthesia without a paravertebral block, you will be given propofol, desflurane, and fentanyl by vein over 1-4 hours during surgery.
Participants in both groups will receive promethazine, famotidine, and dexamethasone at the start of surgery to help decrease or eliminate nausea and vomiting that may occur after surgery.
Follow-up:
After your surgery is complete, before you leave the hospital, you will have the following evaluations:
Length of Study:
Your participation in this study will be over after the 1 week follow-up telephone call.
This is an investigational study. Paravertebral blocks and general anesthesia are FDA approved and commercially available. Up to 89 patients will take part in this study. All will be enrolled at M. D. Anderson.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Paravertebral Block + General Anesthesia | Active Comparator | Group 1: Paravertebral Block + General Anesthesia (Ropivacaine) |
|
| General Anesthesia Alone | Active Comparator | Group 2: General Anesthesia Alone (Propofol, Midazolam, Fentanyl) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Paravertebral Block | Procedure | Paravertebral block given as a bolus injection into the paravertebral space. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Participants With No Pain Immediately After Surgery | Pain assessed using a verbal numeric rating scale (NRS) scored by numeric integers, with scores of 0-10 where 0 is no pain and 10 is the worst pain. Pain evaluated within the first hour, between 1 - 3 hours, between 3 - 6 hours post-operatively. Additional reporting planned for following morning (18 - 24 hours post-operatively). | Starting immediately after surgery, every 2 hours till the 6th hour following surgery |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Farzin Goravanchi, MD | M.D. Anderson Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UT MD Anderson Cancer Center | Houston | Texas | 77030 | United States |
Not provided
| Label | URL |
|---|---|
| MD Anderson Cancer Center | View source |
Not provided
Of the 89 participants enrolled, one participant was excluded prior to group assignment.
Recruitment Period: September 10, 2007 to February 28, 2011. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Group 1: Paravertebral Block + General Anesthesia | Paravertebral Block + General Anesthesia (Ropivacaine) Paravertebral Block: Paravertebral block given as a bolus injection into the paravertebral space. Ropivacaine: Ropivacaine given by injection into the paravertebral space along the spinal canal. |
| FG001 | Group 2: General Anesthesia Alone | General Anesthesia Alone (Propofol, Midazolam, Fentanyl) Propofol: 2-2.5 mg/kg IV over 1-4 hours during surgery. Fentanyl: 50-250 mcg IV over 1-4 hours during surgery. Midazolam: 0.08 mg/kg IV over 1-4 hours during the surgery. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
One participant was removed prior to study randomization.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Group 1: Paravertebral Block + General Anesthesia | Paravertebral Block + General Anesthesia (Ropivacaine) Paravertebral Block: Paravertebral block given as a bolus injection into the paravertebral space. Ropivacaine: Ropivacaine given by injection into the paravertebral space along the spinal canal. |
| BG001 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Proportion of Participants With No Pain Immediately After Surgery | Pain assessed using a verbal numeric rating scale (NRS) scored by numeric integers, with scores of 0-10 where 0 is no pain and 10 is the worst pain. Pain evaluated within the first hour, between 1 - 3 hours, between 3 - 6 hours post-operatively. Additional reporting planned for following morning (18 - 24 hours post-operatively). | Analysis was not possible from data collected due to reporting inconsistencies. | Posted | Starting immediately after surgery, every 2 hours till the 6th hour following surgery |
|
Adverse Event Reporting was from baseline to end of study involvement, approximately 21 days. Overall active study period from December 03, 2007 to March 05 2011.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Group 1: Paravertebral Block + General Anesthesia | Paravertebral Block + General Anesthesia (Ropivacaine) Paravertebral Block: Paravertebral block given as a bolus injection into the paravertebral space. Ropivacaine: Ropivacaine given by injection into the paravertebral space along the spinal canal. |
Not provided
Not provided
The study completed with measurement reporting issues (inconsistencies) leading to uninterpretable data.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Farzin Goravanchi, Professor, Anesthesiology & Perioperative Medicine | University of Texas MD Anderson Cancer Center | 713-563-5613 | CR_Study_Registration@mdanderson.org |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015742 | Propofol |
| D005283 | Fentanyl |
| D000077212 | Ropivacaine |
| D008874 | Midazolam |
| ID | Term |
|---|---|
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Propofol | Drug | 2-2.5 mg/kg IV over 1-4 hours during surgery. |
|
| Fentanyl | Drug | 50-250 mcg IV over 1-4 hours during surgery. |
|
| Ropivacaine | Drug | Ropivacaine given by injection into the paravertebral space along the spinal canal. |
|
| Midazolam | Drug | 0.08 mg/kg IV over 1-4 hours during the surgery. |
|
| Group 2: General Anesthesia Alone |
General Anesthesia Alone (Propofol, Midazolam, Fentanyl) Propofol: 2-2.5 mg/kg IV over 1-4 hours during surgery. Fentanyl: 50-250 mcg IV over 1-4 hours during surgery. Midazolam: 0.08 mg/kg IV over 1-4 hours during the surgery. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG001 | Group 2: General Anesthesia Alone | General Anesthesia Alone (Propofol, Midazolam, Fentanyl) Propofol: 2-2.5 mg/kg IV over 1-4 hours during surgery. Fentanyl: 50-250 mcg IV over 1-4 hours during surgery. Midazolam: 0.08 mg/kg IV over 1-4 hours during the surgery. |
|
| 0 |
| 44 |
| 0 |
| 44 |
| EG001 | Group 2: General Anesthesia Alone | General Anesthesia Alone (Propofol, Midazolam, Fentanyl) Propofol: 2-2.5 mg/kg IV over 1-4 hours during surgery. Fentanyl: 50-250 mcg IV over 1-4 hours during surgery. Midazolam: 0.08 mg/kg IV over 1-4 hours during the surgery. | 0 | 44 | 0 | 44 |
Not provided
Not provided
| D017437 |
| Skin and Connective Tissue Diseases |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D000813 | Anilides |
| D000577 | Amides |
| D000814 | Aniline Compounds |
| D000588 | Amines |
| D001569 | Benzodiazepines |
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |